The study on muscle performance and recovery, published by Aurea Biolabs in Fortune Journals, revealed that Rephyll® (β-Caryophyllene) significantly reduced muscle fatigue compared to the placebo group, as evidenced by improvements in the fatigue index and perceived exertion levels. Participants in the Rephyll® group showed lower respiratory exchange ratios, suggesting improved aerobic performance. They also maintained higher ATP reserves, which was necessary to sustain energy while exercising. Individuals who received Rephyll® reported lower pain scores on the Visual Analog Scale indicating a reduction in the DOMS symptoms. The trial was a randomized, double- blind, placebo-controlled clinical study conducted for 30 days. The participants (105) received either Rephyll® capsules or the placebo daily throughout the study. All volunteers were untrained in resistance or power exercises and tested for changes in muscle fatigue, energy levels, recovery from delayed onset muscle soreness (DOMS), inflammation, and stress.

DOMS refers to muscle pain and stiffness that develops after unfamiliar or intense exercise, particularly those involving eccentric muscle contractions. β-Caryophyllene (BCP), a compound known for its anti-inflammatory and antioxidant properties, has been studied for its ability to alleviate DOMS. Aurea Biolabs developed a novel liposomal powder form of BCP, called Rephyll®, using advanced nanofiber weaving (NFW) technology to improve its bioavailability and stability. BCP selectively interacts with the CB2 endocannabinoid receptor, which is involved in pain management. Rephyll® helps enhance muscle activation, reduce inflammation, support energy levels, and alleviate stress. It was shown to be well-tolerated with no adverse effects, positioning Rephyll® as a safe and effective supplement for pain relief and muscle recovery in athletes and active individuals.